Total assets increased 11.2%
Total assets changed +11.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Total assets changed +11.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Capital expenditure changed -73.4% from the comparable as-filed period.
Operating income changed +11.1% from the comparable as-filed period.
Revenue changed +9.2% from the comparable as-filed period.
Receivables / revenue changed +1802 basis points from the comparable as-filed period.
Operating cash-flow margin changed -1328 basis points from the comparable as-filed period.
Cost of revenue changed +19.0% from the comparable as-filed period.
Operating margin changed +33 basis points from the comparable as-filed period.
Working capital / assets changed +158 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Selling, general & administrative changed -2.9% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Shares outstanding changed +0.3% from the comparable as-filed period. The change ranks at the 0th percentile of 8 prior comparable changes.
Current ratio changed -11.5% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Gross profit changed +4.7% from the comparable as-filed period.
R&D / revenue changed +135 basis points from the comparable as-filed period.
Stock-based compensation changed -13.4% from the comparable as-filed period.
SBC / revenue changed -9 basis points from the comparable as-filed period.
Inventory changed -1.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Selling, general & administrative changed -21.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current liabilities changed +22.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Inventory / revenue changed +994 basis points from the comparable as-filed period.
Revenue changed -1.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current assets changed +14.3% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Working capital changed +13.4% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed -79.3% from the comparable as-filed period.
Receivables / revenue changed +437 basis points from the comparable as-filed period.
Operating cash-flow margin changed -1258 basis points from the comparable as-filed period.
Total assets changed +11.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Research & development changed -6.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Capex / revenue changed +78 basis points from the comparable as-filed period.
Working capital / assets changed +144 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Shares outstanding changed +0.4% from the comparable as-filed period. The change ranks at the 12th percentile of 8 prior comparable changes.
SBC / revenue changed -75 basis points from the comparable as-filed period.
Trade receivables changed +4.8% from the comparable as-filed period.
Inventory changed +3.5% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Current ratio changed -6.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Gross profit changed +1.8% from the comparable as-filed period.
Cost of revenue changed -7.7% from the comparable as-filed period.
R&D / revenue changed -44 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.